• Feb 4, 2011 - ClaremontBio Would Like to Recognize Our Very Own Mark Brown for His Mention in Science Magazine's "Issues and Perspectives" Feature
ClaremontBio
is proud to announce that senior scientist
Mark Brown, Ph.D. was recently quoted and featured in the weekly “Issues and
Perspectives” column in Science Magazine. The article presents Mark’s graduate
and post-graduate educational experiences and his advice for recent Ph.D.
graduates. The article also mentions Mark’s recruitment by ClaremontBio and how
his valuable post-PhD education experience has already been of great benefit.
Read the Full Article
• July 21, 2010 - ClaremontBio Exhibits for AACC Clinical Lab Expo
ClaremontBio is pleased to announce our participation as an exhibitor at the American Association for Clinical Chemistry (AACC) Clinical Lab Expo to be held at the Anaheim Convention Center on 07/27-07/29. It is estimated that there will be 20,000 attendees ranging from lab directors, managers, supervisors and key decision makers. Nearly 90% of GPO executives report that the Clinical Lab Expo is the only show attended each year, so if you plan to be in attendance at this prestigious event, please feel free to visit us in the OEM section of this show at booth number 603. We look forward to seeing you there!
Visit the AACC at: www.aacc.org
• Oct 9, 2009 - ClaremontBio is Selected by NIH to Receive Technology Niche Analysis
The National Institute of Health (NIH) has recognized ClaremontBio as one of only fifty 2009 NIH SBIR (Small Business Innovation Research) awardees to receive a supplemental award of having a Technology Niche Analysis (TNA™)performed by Foresight Science & Technology on the core technology developed in the SBIR. ClaremontBio’s eligible NIH Phase 1 SBIR project is entitled “A fully integrated assay and platform for detecting Clostridium difficile.”
Read the full press release
• Feb, 2009 - ClaremontBio Receives Phase I Small Business Innovative Research GrantClaremontBio is proud to announce that it has received a Phase I Small Business Innovative Research Grant from the National Institute of Health today in an effort to combat the problem of hospital acquired infections (HAI). ClaremontBio proposes to develop a point-of-care (POC) device to rapidly extract DNA from clinical samples and/or swabs from medical devices, amplify DNA using an isothermal amplification reaction (developed by Ionian Technologies), and detect amplified nucleic acid using miniaturized real-time fluorimetry. The primary target pathogen that the ClaremontBio team will be focused upon for this project will be Clostridium difficile a common causative agent in enteric disease. Certain highly virulent strains are also associated with more severe morbidity and even mortality in some patients Read the full press release
• July 1, 2008 - Claremont BioSolutions Moves to New Location
Claremont BioSolutions LLC (ClaremontBio) is pleased to announce the leasing approximately 1900 sq. ft. of office, laboratory, and manufacturing space at 1182 Monte Vista Ave., Suite 11 & 12, Upland, CA 91786.
The new location allows for several key benefits such as elements of prototype design, processing of raw materials, device assembly, and subsequent biological testing of completed devices.
• May 6, 2008 - Claremont BioSolutions Licenses Technologies for Nucleic Acid Diagnostics from Keck Graduate Institute
Claremont BioSolutions announced today that it has entered into a licensing agreement with Keck Graduate Institute for exclusive, worldwide rights to biological sample preparation and biological detection methods for fluorescence detection of isothermal nucleic acid amplification. In addition, Claremont BioSolutions has been granted incubation status that provides limited KGI office and laboratory space with access to bioengineering and microfluidics laboratory equipment and facilities.
• April 7, 2008 - Claremont BioSolutions presents performance data for real-time isothermal fluorimetry and lysis technology at LabAutomation 2008 Meeting, Palm Springs, CA
Claremont BioSolutions presented recent results on three systems that have been developed as components for molecular diagnostics. Results were presented for two-color real-time flourimetry of isothermal DNA amplification reactions, as well as the performance of rapid and efficient lysis systems used to access the DNA in hard-to-lyse biological samples.
See ClaremontBio's Data
Visit the LabAutomation website
• April, 2008 - Claremont BioSolutions Announces NIH Phase II SBIR Program for Herpes Simplex Virus Detection
The goal of this project is to develop next-generation molecular diagnostic assays for the detection of HSV in hospital clinical settings. The three-year program will allow completion of clinical trials leading to FDA clearance of a diagnostic system based on the Helicase Dependent Amplification (HDA) reaction with real-time detection using fluorometer units developed by Claremont BioSolutions.
Learn more about ClaremontBio's technology
• February 1, 2008 - Claremont BioSolutions presents sample preparation results at Department of Homeland Security Meeting, San Antonio, TX
Claremont BioSolutions presented data on the performance the Micro Bead-Beater™ (μBB™) and microfluidic bead blender components. Lysis efficiency, speed, and the unique flow-through configuration were presented through use of real-time PCR as well as nanoscale imaging using SEM, TEM and AFM techniques.
See ClaremontBio's Data
|
